Patients with atrial fibrillation (AF) are at an approximately 0.5% to 3% increased risk of thromboembolism during and immediately after catheter ablation. Treatment guidelines recommend periprocedural oral anticoagulation plus unfractionated heparin during ablation. Rivaroxaban and dabigatran are the only non-vitamin K oral anticoagulants for which there are randomized controlled trials assessing uninterrupted anticoagulation in patients undergoing catheter ablation of AF. Edoxaban, a direct factor Xa inhibitor, is noninferior vs warfarin for the prevention of stroke or systemic embolism with less major bleeding in patients with nonvalvular AF. The ELIMINATE-AF (Evaluation of Edoxaban Compared With VKA in Subjects Undergoing Catheter Ablation of Nonvalvular Atrial Fibrillation) trial is a multinational, multicenter, prospective, randomized, open-label, parallel-group, blinded-endpoint evaluation (PROBE) study to assess the safety and efficacy of once-daily edoxaban 60 mg (30 mg in patients indicated for a dose reduction) vs vitamin K antagonists (VKA) in patients with nonvalvular AF undergoing catheter ablation (http://www.ClinicalTrials.gov: NCT02942576). A total of 560 patients are planned for randomization to edoxaban or VKA (2:1 ratio) to obtain 450 patients fully compliant with the protocol. Patients will complete 21 to 28 days of anticoagulation prior to the ablation and a 90-day post-ablation period. The primary efficacy endpoint is the composite of all-cause death, stroke, and major bleeding. The primary safety endpoint is major bleeding. A magnetic resonance imaging substudy will assess the incidence of silent cerebral lesions post-ablation. ELIMINATE-AF will define the efficacy and safety of edoxaban for uninterrupted oral anticoagulation during catheter ablation of AF.

Arrhythmia and Electrophysiology Research Center Humanitas Clinical and Research Center Rozzano Italy

Cardiology Clinical Academic Group Molecular and Clinical Sciences Research Institute St George's University of London London UK

Department of Cardiac Sciences Division of Cardiology Libin Cardiovascular Institute University of Calgary Calgary Alberta Canada

Department of Cardiology Antwerp University Hospital University of Antwerp Antwerp Belgium

Department of Cardiology Hospital Clinic University of Barcelona Barcelona Spain

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Global Medical Affairs Daiichi Sankyo Europe GmbH Munich Germany

Department of Neurology University Hospital Essen and Medical Faculty of the University Duisburg Essen Essen Germany

Division of Clinical Electrophysiology Department of Cardiology J W Goethe University Frankfurt Germany

Pharma Development Modeling and Simulation Daiichi Sankyo Basking Ridge New Jersey

Zobrazit více v PubMed

Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta‐analyses. Circ Arrhythm Electrophysiol. 2009;2:349–361. PubMed

Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32–38. PubMed

January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published correction appears in J Am Coll Cardiol. 2014;64:2305–2307]. J Am Coll Cardiol. 2014;64:e1–e76. PubMed

Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow‐up, definitions, endpoints, and research trial design. Europace. 2012;14:528–606. PubMed

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS [article in English, Spanish; published correction appears in Rev Esp Cardiol (Engl Ed). 2017;70:1031]. Rev Esp Cardiol (Engl Ed). 2017;70:50.e1–50.e84. PubMed

Oral H, Chugh A, Ozaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation. 2006;114:759–765. PubMed

Vazquez SR, Johnson SA, Rondina MT. Peri‐procedural anticoagulation in patients undergoing ablation for atrial fibrillation. Thromb Res. 2010;126:e69–e77. PubMed PMC

Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation. 2014;129:2638–2644. PubMed

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta‐analysis of randomised trials. Lancet. 2014;383:955–962. PubMed

Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14:e275–e444. PubMed PMC

Calkins H, Willems S, Gerstenfeld EP, et al; RE‐CIRCUIT Investigators . Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376:1627–1636. PubMed

Cappato R, Marchlinski FE, Hohnloser SH, et al; VENTURE‐AF Investigators . Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non‐valvular atrial fibrillation. Eur Heart J. 2015;36:1805–1811. PubMed PMC

Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non‐vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55:641–655. PubMed PMC

Savaysa (edoxaban) tablets [full prescribing information] . Parsippany, NJ: Daiichi‐Sankyo Inc., 2015.

Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE‐AF TIMI 48 Investigators . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. PubMed

Steffel J, Ruff CT, Hamershock RA, et al. First experience with edoxaban and atrial fibrillation ablation: insights from the ENGAGE AF‐TIMI 48 trial. Int J Cardiol. 2017;244:192–195. PubMed

Lip GY, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J. 2014;35:1844–1855. PubMed

Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel‐group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633–641. PubMed

Rodeghiero F, Tosetto A, Abshire T, et al; ISTH/SSC Joint VWF and Perinatal/Pediatric Hemostasis Subcommittee Working Group . ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063–2065. PubMed

Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736–2747. PubMed

Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142–154. PubMed

Herrera Siklódy C, Deneke T, Hocini M, et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol. 2011;58:681–688. PubMed

Deneke T, Shin DI, Balta O, et al. Postablation asymptomatic cerebral lesions: long‐term follow‐up using magnetic resonance imaging. Heart Rhythm. 2011;8:1705–1711. PubMed

Haeusler KG, Koch L, Herm J, et al. 3 Tesla MRI‐detected brain lesions after pulmonary vein isolation for atrial fibrillation: results of the MACPAF study. J Cardiovasc Electrophysiol. 2013;24:142017. PubMed

Zhao Y, Yang Y, Tang X, et al. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta‐analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin. J Interv Card Electrophysiol. 2017;48:267–282. PubMed

Aryal MR, Ukaigwe A, Pandit A, et al. Meta‐analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol. 2014;114:577–582. PubMed

Phan K, Wang N, Pison L, et al. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: a meta‐analysis. Int J Cardiol. 2015;185:209–213. PubMed

Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta‐analysis of the literature. Europace. 2013;15:1407–1411. PubMed

Nogami A, Machino T, Harada T, et al; ABRIDGE‐J Study Group . Clinical benefit of minimally interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial. Circulation. 2017;136:e448–e467. PubMed

Di Biase L, Callans D, Haeusler KG, et al. Rationale and design of AXAFA‐AFNET 5: an investigator‐initiated, randomized, open, blinded outcome assessment, multi‐centre trial comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace. 2017;19:132–138. PubMed

Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02942576